THU072 Association Between Nonalcoholic Fatty Liver Disease And Growth Hormone Deficiency In Patients With Nonfunctioning Pituitary Adenoma

Disclosure: Y. Hwang: None. H. Lee: None. S. Ahn: None. E. Lee: None. C. Ku: None. S. Kim: None. Objective: We investigated the association between nonalcoholic fatty liver disease (NAFLD) and growth hormone deficiency (GHD) in patients with non-functioning pituitary adenoma (NFPA). Methods: Patients with NFPA who underwent transsphenoidal adenectomy between January 2005 and December 2018 were recruited. Pituitary function was determined by the insulin tolerance test, thyroid hormone assay, and gonadal hormone levels. NAFLD was defined as a hepatic steatosis index greater than 36. Results: 278 patients were included for the analysis. Mean age was 44.2 years and 58.6%[n=163] patients were female. Among 278 patients,103 (37.0%) had GHD, 139 (50.0%) had hypogonadism. 75 out of 278 patients (27.0%) had NAFLD. The prevalence of NAFLD was significantly higher in patients with GHD than in those without (36.9% vs. 21.1%, p=0.01). Even after adjusting for age, total cholesterol level, gonadal function, and prolactin level, patients with GHD had approximately two-fold higher prevalence of NALFD than those without GHD (adjusted odds ratio [OR]=1.85, 95% confidence interval [CI]=1.05-3.28, p=0.03). Among female patients, the prevalence of NALFD was significantly higher in those with GHD than in those without (adjusted OR=2.39, 95% CI=1.03-5.55, p=0.04). On the other hand, the prevalence of NAFLD among male patients was statistically similar between patients with and without GHD (p>0.05). In addition, gonadal function did not affect the prevalence of NAFLD in patients with NFPA (29.3% with eugonadism vs. 47.8% with hypogonadism, p=0.14). Conclusion: The prevalence of NAFLD among patients with NFPA was twice as high as among patients without GHD. Thus, screening for NAFLD may be necessary in NFPA patients with GHD. Presentation: Thursday, June 15, 2023